Status:
COMPLETED
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
Lead Sponsor:
Sumitomo Pharma America, Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
Detailed Description
Study will evaluate long-term safety and tolerability of a new compound in the treatment of patients with schizophrenia as assessed by adverse events (AEs), measures of extra pyramidal symptoms (EPS; ...
Eligibility Criteria
Inclusion
- Patients must have participated in study D1050196 (A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia) and either:
- Successfully completed
- OR
- Patients must have been discontinued after a minimum of 2 weeks of treatment due to lack of efficacy
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00088621
Start Date
July 1 2004
End Date
October 1 2005
Last Update
April 17 2014
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Psychiatry Pharmaceutical
Birmingham, Alabama, United States, 35209
2
Summit Research Group
Little Rock, Arkansas, United States, 72211
3
Comprehensive NeuroScience
Cerritos, California, United States, 90703
4
Collaborative Neuro Science Network, Inc.
Garden Grove, California, United States, 92845